Mark Tarnopolsky

Dr Mark Tarnopolsky

Co-Applicant

Professor of Pediatrics and Medicine, Director of Neuromuscular and Neurometabolic Clinic, McMaster University Medical Center

CEO/CSO Exerkine Corporation


NMD4C Involvement: Pillar 1: Preclinical Science

Email Mark

Research Interests: Mitochondrial disease, Neurogenetic diagnostics, Neurometabolic disorders, MD therapeutics, Aging/sarcopenia, Obesity

Academic web profile
Google Scholar profile

Biography

Dr. Tarnopolsky is a neuromuscular and neurometabolic clinician-scientist who received an MD and PhD (Cell Biology and Metabolism) from McMaster University.  He currently holds an endowed chair from McMaster Children’s Hospital Foundation in the area of neuromuscular and neurometabolic genetic disorders and follows over 1500 patients with myopathies, mitochondrial disorders and other neurogenetic disorders. He has published over 500 peer reviewed papers and has an h-index of 142.  His research focuses on pharmacological, nutraceutical and exercise therapies for neuromuscular and neurometabolic disorders, aging, obesity and other disorders that affect the mitochondria and muscle function.  He is the founder, CEO and CSO of Exerkine Corporation which is a bio-technology/nutraceutical company developing therapies for aging, obesity, muscular dystrophy and mitochondrial disorders.


Recent Publications

Chiarot, A, Minhas, M, de Maat, NM, Doan, J, Nilsson, MI, Hettinga, BP et al.. A Multi-Ingredient Supplement Improves Body Re-Composition, Ovarian Aging Markers, and Reproductive Success in Young and Middle-Aged Female Mice. Biomolecules. 2025.15 (9) PMID:41008565

Nederveen, JP, Nilsson, MI, Tarnopolsky, MA. Multi-ingredient supplementation for combating sarcopenia and polymorbidity. Curr Opin Clin Nutr Metab Care. 2025.28 (6)452-462 PMID:40960165

Menetrey, A, Tarnopolsky, M, Yoganathan, S, Shroff, M, Gorodetsky, C. Child Neurology: Clinical and Imaging Findings in a Child With DHX37 Gene Variant: A Ribosomopathy Masquerading as Cerebral Palsy. Neurology. 2025.105 (7)e214126 PMID:40934457

Xhuti, D, Chiarot, A, Minhas, M, Tobia, S, de Maat, N, Manta, K et al.. Combination treatment with antioxidants and creatine alleviates common and variant-specific mitochondrial impairments in Leber's hereditary optic neuropathy patient-derived fibroblasts. Hum Mol Genet. 2025.34 (21)1780-1795 PMID:40879302

Al-Mhanna, SB, Poon, ET, Franklin, BA, Tarnopolsky, MA, Hawley, JA, Jakicic, JM et al.. Comparative effectiveness of high-intensity interval training and moderate-intensity continuous training on cardiometabolic health in patients with diabesity: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025.17 (1)331 PMID:40804647

Karaa, A, Goldstein, A, Cohen, BH, Haas, RH, Vockley, J, Gorman, GS et al.. RePOWER: An International, Prospective, Non-Interventional Registry of Patients With Primary Mitochondrial Myopathy. Clin Genet. 2025. PMID:40785393

Grafham, GK, Mak, G, Grant, S, Murphy, A, Baker, SK, Tarnopolsky, M et al.. Intracellular amyloidosis in peripheral nerve and skeletal muscle. J Neuropathol Exp Neurol. 2025.84 (11)978-988 PMID:40700473

Candow, DG, Ostojic, SM, Chilibeck, PD, Longobardi, I, Gualano, B, Tarnopolsky, MA et al.. Creatine monohydrate supplementation for older adults and clinical populations. J Int Soc Sports Nutr. 2025.22 (sup1)2534130 PMID:40673730

Ostojic, SM, Candow, DG, Tarnopolsky, MA. Creatine and post-viral fatigue syndrome: an update. J Int Soc Sports Nutr. 2025.22 (sup1)2517278 PMID:40481620

Nava, C, Cogne, B, Santini, A, Leitão, E, Lecoquierre, F, Chen, Y et al.. Dominant variants in major spliceosome U4 and U5 small nuclear RNA genes cause neurodevelopmental disorders through splicing disruption. Nat Genet. 2025.57 (6)1374-1388 PMID:40379786

See more on PubMed